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Western Blot. Prostaglandin E2 (PGE2) and metalloproteinase-13 (MMP-
13) levels as well as glutathione S-transferase (GST) activity were
each assessed with commercial kits. NO release was determined using
improved Griess method. Reactive oxygen species (ROS) generation was
revealed using ﬂuorescent microscopy with the use of commercial kits.
Results: L-NIL prevented IL-1b-induced NO release, iNOS expression at
protein and mRNA levels, S-nitrosylated proteins and HNE in a dose
dependent manner after 24h of incubation. Interestingly, we revealed
that L-NIL abolished IL-1b-induced NOX component p47phox. The HNE-
induced PGE2 release and both cyclooxygenase-2 (COX-2) and MMP-13
expression were signiﬁcantly reduced by L-NIL addition. Furthermore,
L-NIL blocked the IL-1b induced inactivation of GST, an HNE-metabolizing
enzyme. Also, L-NIL prevented HNE induced cell death at cytotoxic
levels.
Conclusions: Altogether, our ﬁndings support a beneﬁcial effect of L-NIL
in OA by preventing LPO process in NO-dependent and/or independent
mechanisms.
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INHIBITION OF WNT/b-CATENIN SIGNALING CAN BLOCK IL1b/TNFa
INDUCED CARTILAGE DEGRADATION IN A MURINE EX VIVO MODEL
E. Landman1, R. Miclea2, C. van Blitterswijk1, M. Karperien1. 1Univ. of
Twente, Enschede, Netherlands; 2Univ. Med. Ctr. Leiden, Leiden, Netherlands
Purpose: Osteoarthritis (OA) is a very common and disabling disease
that is characterized by progressive articular cartilage loss, synovial
inﬂammation and subchondral bone changes. Even though the primary
etiology of OA remains undetermined, it is believed that a disbalance
between anabolic and catabolic processes that normally occur in cartilage
underlies the pathophysiology. A disturbance of the Wnt/b-catenin sig-
naling pathway is believed to be involved in this. Conditional activation
of b-catenin in mice results in an OA-like articular destruction of articular
cartilage and it has been shown that mice, in which the Wnt antagonist
FRZb is knocked out, are more susceptible to chemically induced OA.
Therefore, we studied the effect of inhibition of the Wnt/b-catenin
signaling pathway on IL1b and TNFa induced cartilage degradation in
mouse fetal metatarsals. We have selected three small molecules that
inhibit binding of b-catenin to its transcription factors TCF and LEF.
Methods: We isolated the three middle metatarsals from fetal FVB
mouse embryos at day 17.5 of gestation. Metatarsals were cultured for an
equilibration period of 48 hours before treatment with IL1b/TNF and the
small molecules, which were added to the metatarsals simultaneously.
Metatarsals were treated for 1, 4 or 7 days for histology (n =2), for 1 or
4 days for gene expression analysis (pooled 5 metatarsals, n = 2) and for
7 days for glycosaminoglycan (GAG) quantiﬁcation (n =5). Pictures were
taken at different time points for morphometric analysis.
Results: Morphometric analysis of the metatarsals showed that the
longitudinal growth of the metatarsals is impaired by treatment with IL1b
and TNFa. In addition, the cytokines caused severe folding and shriveling
up of the metatarsals which was increasing over time due to cartilage
degradation. Addition of the small molecules prevented these catabolic
effects. Furthermore, they inhibited the loss of GAGs and collagen II from
the extracellular matrix induced by IL1b and TNFa.
Conclusions: In conclusion, we prove that inhibition of the binding of
b-catenin to its transcription factors TCF and LEF can prevent IL1b and
TNFa induced cartilage degradation in mouse fetal metatarsals. Since
IL1b plays an important role in cartilage degradation in OA, inhibition
b-catenin activity might be a new therapeutic option for OA.
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SALMON CALCITONIN PREVENTED CHONDROCYTE HYPERTROPHY
EX VIVO
P. Chen-An, K. Henriksen, M.A. Karsdal, A-C. Bay-Jensen. Nordic BioSci.
A/S, Herlev, Denmark
Purpose: Chondrocyte hypertrophy is a key event of the pathogenesis
of osteoarthritis (OA), which leads to cartilage calciﬁcation. To inhibit or
prevent the hypertrophy would contribute to inhibit or delay the onset
of early OA. Calcitonin is widely used as an anti-resorptive agent for
the treatment of osteoporosis. However, the application of calcitonin in
treatment of joint degenerative disease has likewise been investigated,
but is less understood. The effect of calcitonin on cartilage hypertrophy
and calciﬁcation is yet to be understood. The aim of our work was
to investigate the effect of salmon calcitonin (sCT) on hypertrophic
chondrocytes, in a well characterized and validated ex vivo model.
Methods: Full depth cartilage (FDC) explants (from superﬁcial to calciﬁed
cartilage) were isolated from bovine femoral condyle and hypertrophy
was induced by culture for 4 days with triiodo-L-thyronine (T3)
stimulation. Non-stimulated explants were cultured as control (W/O).
Doses of sCT ranged from 1nM to 100nM were added from day 0 to
day 4. Type X collagen (COL X) localization on hypertrophic chondrocytes
was analyzed by immunohistochemistry. Calcitonin receptor (CTR)
expression was evaluated by RT-PCR. Cartilage turnover was measured by
biochemical markers of type II collagen (COL II) formation (PIINP assay)
and degradation (CIIM assay). A sandwich ELISA assay – AGNx-II was
used for measuring aggreacan degradation. As markers of hypertrophic
chondrocytes, Indian hedgehog (IHH), COL X, alkaline phosphatase (ALP)
and matrix metallopeptidase 13 (MMP-13) were evaluated using RT-
PCR. Histological analysis was used for chondrocytes morphological
measurement.
Results: Hypertrophy was induced by 4 days stimulation with
T3. Hypertrophic chondrocytes expressed COL X, visualized by
immunohistochemistry as brown color around the cells. The induction
of hypertrophy led to a ~10 fold higher CTR mRNA expression
than W/O (p < 0.05). sCT increased COL II formation and decreased
aggreacan degradation dose-dependently, comparing with T3 induced
hypertrophy. In contrast, T3 induced signiﬁcant release of CIIM fragments
compared with W/O (p < 0.01). sCT showed a suppression effect on
COL II degradation, whereas the CIIM level still higher than control.
The induction of hypertrophy had signiﬁcant higher expression of
Ihh (p < 0.01), COL X (p < 0.001) and ALP (p < 0.001) compared with
control, where MMP-13 expression was also higher than control but
not signiﬁcantly. 1nM and 10nM sCT both suppressed the expression
of the four markers of hypertrophic chondrocytes, in which 10nM
inhibited the expression of Ihh, COL X and ALP signﬁciantly (p < 0.05). On
the contrary, 100nM increased the expression of the four hypertrophy
markers signiﬁcantly (p < 0.01). Chondrocytes morphology showed that
1nM and 10nM sCT treated explants had less hypertrophic chondrocytes,
where 100nM sCT had comparable hypertrophic chondrocytes compared
with T3 treated explants.
Conclusions: In our model, T3 induced hypertrophic chondrocytes at
day4. The expression of calcitonin receptor was highly upregulated
in hypertrophic chondrocytes compared the non-hypertrophic
chondrocytes. T3 induced hypertrophic chondrocytes had signiﬁcant
increased level of cartilage degradation. sCT suppressed expression of
markers of hypertrophic chondrocytes and cartilage degradation, in
which 10nM sCT is more promising. Our study demonstrated that
calcitonin treatment prevented chondrocyte hypertrophy in this ex vivo
model.
495
TOWARD CARTILAGE DRUG DELIVERY: PEPTIDE CELL ASSOCIATION
VIA THE TAT-PTD IN PRIMARY HUMAN CHONDROCYTES
R.K. June1, D.C. Brinson2, M.K. Lotz2, S.F. Dowdy1. 1Univ. of California, San
Diego, La Jolla, CA, USA; 2The Scripps Res. Inst., La Jolla, CA, USA
Purpose: Delivery of bioactive molecules to articular chondrocytes is a
major challenge toward creating effective treatments for osteoarthritis.
Intra-articular delivery of standard therapeutics is limited by short
residence times because of diffusion to synovial capillary beds resulting
in active export from the joint. The TAT Peptide Transduction Domain
(PTD) is a cationic 9 amino acid peptide from the HIV TAT protein that has
been successfully used to deliver a variety of macromolecules (peptides,
proteins, siRNAs) to numerous cell types. The purpose of this study was
to determine if the TAT PTD could enable cell-association of peptides in
primary human chondrocytes from a wide variety of donors.
Methods: Rhodamine-labeled peptides were synthesized using solid-
phase peptide synthesis with Fmoc protection in 25mM scale on a
Symphony Quartet peptide synthesizer. All peptides were cleaved and
deprotected using a standard protocol (95% triﬂuoroacetic acid, 1%
water, 1% triisopropylsilane). Crude peptides were precipitated using cold
diethylether and puriﬁed using prep-scale reversed-phase HPLC with a
C18 column; purity was conﬁrmed by MALDI-TOF mass spectrometry
using the matrix a-CHCA. Primary human chondrocytes (n =6) were
harvested from human cadaveric tissue via enzymatic digestion and
grown in DMEM with 10% fetal calf serum. For experiments, 50,000
cells per well were plated in 12 well plates. Two days later cells were
washed with HBSS and treated with control or TAT-peptides (1.25, 2.5,
or 5mM) for 1 hour or left untreated. Following treatment, cells were
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washed three times with HBSS containing 0.5mg/mL heparin sulfate,
detached with accutase, and resuspended in growth media for analysis.
Cell-associated ﬂuorescence was measured via ﬂow cytometry. Live cells
were discriminated via forward and side scatter; cell association was
quantiﬁed using the mean ﬂuorescence intensity (MFI). At each dosage,
MFI values between control and TAT-peptides were compared using
paired t-tests with an a priori signiﬁcance level of 0.05.
Results: The TAT-PTD resulted in signiﬁcantly more cell-associated
ﬂuorescence than the control peptide in a dose-dependent manner
implying that intracellular uptake was facilitated. The MFI values
for TAT-Treated cells (MFI: 313±61, 686±136, 2430±271 for peptide
concentrations of 1.25, 2.5, and 5mM, respectively) were signiﬁcantly
greater than those (110±15, 156±25, 280±36 for 1.25, 2.5, and 5mM,
respectively) for the chondrocytes treated with the control peptide (all
p ≤ 0.02). Cell association of TAT peptides was observed in various types
of chondrocytes from both male and female donors, from donors ranging
in age from 24 to 64, and from normal and OA donors.
Conclusions: These data suggest that the TAT protein transduction
domain facilitates peptide-uptake in primary human chondrocytes from
diverse donor populations with varying age and OA grades. Future studies
will determine whether the TAT PTD can be used to deliver therapeutic
molecules to in vivo articular cartilage for modulating chondrocyte
behavior toward treating osteoarthritis.
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PHELLODENDRON AMURENSE REGULATE THE LEVELS OF MATRIX
METALLOPROTEINASES, PROINFLAMMATORY CYTOKINES AND
SIGNALING OF THE MITOGEN ACTIVATED PROTEIN KINASE
(MAPK) PATHWAY IN HUMAN OSTEOARTICULAR CARTILAGE AND
CHONDROCYTES
J. Huh1, Y-H. Baek2, J-D. Lee3, D-Y. Choi3, D-S. Park2. 1Oriental Med. Res.
Ctr. for Bone & Joint Disease, East-West Bone & Joint Inst., Kyung Hee Univ.,
Seoul, Korea, Republic of ; 2Kyung Hee Univ. Hosp. at Kangdong, Kyung Hee
Univ., Seoul, Korea, Republic of ; 3Dept. of Acupuncture & Moxibustion, Coll.
of Oriental Med., Kyung Hee Univ., Seoul, Korea, Republic of
Purpose: Traditional medicine has widely been used Phellodendron
amurense Rupr. (Rutaceae) to treat various inﬂammatory diseases
including arthritis. In this study, we investigated the effects of
Phellodendron amurense (P. amurense) in protecting cartilage, including
regulating the levels of aggrecanases, matrix metalloproteinases
(MMPs)/tissue inhibitor of metalloproteinase (TIMP), proinﬂammatory
cytokines and signaling of the mitogen activated protein kinase (MAPK)
pathway in human osteoarticular cartilage and chondrocytes.
Methods: Explants from human osteoarthritis cartilage were cultured
alone or in IL-1a for 7 days with or without P. amurense ethanol
extract or celecoxib (40, 100, 200mg/ml). The effect of P. amurense on
matrix degradation induced by IL-1a in human articular cartilage was
assessed by staining, and the quantities of sulfated glycosaminoglycan
(GAG) and type II collagen were calculated from the culture media.
The levels of aggrecanases, MMPs, TIMP, and PGE2 in the culture
media were investigated using an enzyme-linked immunosorbent assay
(ELISA). In addition, reverse transcription polymerase chain reaction (RT-
PCR) evaluated the mRNA expression of aggrecanases, MMPs and TIMP.
Furthermore, Western blot analysis was performed to identify the roles
that P. amurense played in the ERK, JNK and p38 signaling pathways.
Results: P. amurense showed no evident cytotoxicity on human
articular cartilage. P. amurense signiﬁcantly inhibited the IL-1a-induced
degradation of GAG and type II collagen from human osteoarticular
cartilage in a concentration-dependent manner. Celecoxib did not
signiﬁcantly inhibit IL-1a-induced release of GAG and only slightly
reduced type II collagen. P. amurense also dose-dependently decreased
the levels of aggrecanase-1 and -2, MMP-1, -3, and -13, whereas it
increased TIMP-1 expression in human osteoarticular cartilage. Celecoxib
only decreased MMP-1 and MMP-13 levels in human osteoarticular
cartilage. In addition, P. amurense reduced the phosphorylation of
extracellular signal regulated kinase (ERK)1/2, Jun NH2-terminal kinase
(JNK) and activated phospho-p38 MAPK in a dose-dependent manner in
human osteoarthritic chondrocytes.
Conclusions: P. amurense inhibited osteoarticular cartilage and
chondrocyte destruction by inhibiting proteoglycan release and type
II collagen degradation, down-regulating aggrecanases, MMP activities
and phospho-ERK1/2, JNK and p38 MAP kinase signalling, and up-
regulating TIMP-1 activity. Therefore, our results suggest that P. amurense
is a potential therapeutic agent to protection cartilage against OA
progression.
Acknowledgement: This work was supported by the National Research
Foundation of Korea Grant funded by the Korean Government (2010–
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THERAPY SWITCHING, ADD-ON, AND DISCONTINUATION IN PATIENTS
WITH OSTEOARTHRITIS IN THE UNITED KINGDOM
M. Gore1, A. Sadosky2, D. Leslie3, K-S. Tai4, P. Emery5. 1Avalon
Hlth.Solutions, Inc, Philadelphia, PA, USA; 2Pﬁzer, Inc., New York, NY, USA;
3Penn State Coll. of Med., Hershey, PA, USA; 4Avalon Hlth.Solutions, Inc.,
Philadelphia, PA, USA; 5Leeds Inst. of Molecular Med., Univ. of Leeds, Leeds,
United Kingdom
Purpose: To evaluate the patterns of therapy switching, add-on and
discontinuation after initiation of treatment with select currently
recommended treatments in patients with OA.
Methods: Using the United Kingdom THIN (The Health Improvement
Network) database, patients at least 18 years of age, with at
least two healthcare encounters with an associated diagnosis of
OA starting January 1, 2005, with the two diagnoses being at
least 30 days apart, newly prescribed (index event) non-selective
nonsteroidal anti-inﬂammatory drugs (NS-NSAIDs, N =6,639; average age
± SD, 67.2±11.4 years), Cyclooxygenase-2 inhibitors (Cox-2s, N =542;
68.0±11.2 years), acetaminophen (N=3,215; 74.1±10.1 years), tramadol
(N=1,724; 70.1±11.2 years), weak opioids (N=5,886; 70.4±11.1 years)
and strong opioids (N=178; 74.0±11.3 years) within 30 days prior,
or anytime after the ﬁrst diagnosis of OA were selected. Descriptive
statistics, Kaplan Meier analyses, and COX proportional hazards model
were used to evaluate patterns of therapy switching, add-on, and discon-
tinuation during the 12-months post-index period. The study protocol
was approved by the Cambridgeshire 4 Research Ethics Committee.
Results: Substantial proportions of OA patients switched therapy within
a year after treatment initiation and rates of therapy switching were
signiﬁcantly different (p < 0.0001) across the evaluated drugs groups: NS-
NSAIDs, 30.0%; Cox-2s, 44.6%; acetaminophen, 32.8%; tramadol, 57.8%;
weak opioids, 33.7%; and strong opioids, 59.6%. Patterns of therapy
add-on at 12-months were also signiﬁcantly (p < 0.0001) different,
although rates of therapy add-on were much lower: NS-NSAIDs, 9.1%;
Cox-2s, 13.5%; acetaminophen, 9.1%; tramadol 11.8%; weak opioids,
8.7%; and strong opioids, 15.2%. A majority of patients in each group
discontinued therapy during the 12-months post-index period (91.9%,
86.9%, 91.4%, 89.7%, 93.2%, and 84.3% of patients in the NS-NSAIDs, Cox-
2s, acetaminophen, tramadol, weak opioids and strong opioids groups,
respectively). An evaluation of estimated probabilities suggested that
over two thirds of patients who switched, augmented or discontinued
therapy did so within the ﬁrst 2-months, and a majority did so within
6-months of treatment initiation.
Conclusions: Results of this study suggest that therapy switching
and discontinuation were very common among OA patients initiating
treatment with the currently recommended medication classes for
this painful condition. The observed high rates of therapy switching
and discontinuation may be indicative of inadequate pain relief or
potentially intolerable side-effects of therapies. Given the human and
economic burden of OA, future research may beneﬁt from a focus
on comparative efﬁcacy and safety parameters to further differentiate
treatment options.
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BIPHASIC POSITIVE EFFECT OF FORMONONETIN ON METABOLIC
ACTIVITY OF HUMAN NORMAL AND OSTEOARTHRITIC SUBCHONDRAL
OSTEOBLASTS
J. Huh1, D-M. Seo2, D-Y. Choi2, Y-H. Baek3, D-S. Park3, J-D. Lee4. 1Oriental
Med. Res. Ctr. for Bone & Joint Disease, East-West Bone & Joint Inst., Kyung
Hee Univ., Seoul, Korea, Republic of ; 2bDept. of Acupuncture & Moxibustion,
Coll. of Oriental Med., KyungHee Univ., Seoul, Korea, Republic of ; 3Kyung
Hee Univ. Hosp. at Kangdong, Kyung Hee Univ., Seoul, Korea, Republic of ;
4bDept. of Acupuncture & Moxibustion, Coll. of Oriental Med., Kyung Hee
Univ., Seoul, Korea, Republic of
Purpose: Osteoarthritis is a multifactorial disease characterized by
loss of articular cartilage and subchondral plate thickening. Therefore,
